CLONAZEPAM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H10ClN3O3
Molecular Weight	315.7117
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1ccc(c(c1)C2=NCC(=Nc3ccc(cc32)N(=O)=O)O)Cl

InChI

InChIKey=DGBIGWXXNGSACT-UHFFFAOYSA-N

InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

HIDE SMILES / InChI

Molecular Formula	C15H10ClN3O3
Molecular Weight	315.7117
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017533s053,020813s009lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/25798598

Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. Klonopin is the brand name for Clonazepam, an anxiolytic and anticonvulsant. The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
GABA-A receptor; anion channel 189 Target ID: CHEMBL2093872 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017533s055lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/8727390 \| https://www.ncbi.nlm.nih.gov/pubmed/25798598	Agonist 2470	0.06 nM [EC50]
GABA-A receptor; alpha-1/beta-2/gamma-2 21 Target ID: CHEMBL2095172 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25798598	Agonist 2470	57.0 µM [EC50]
GABA A receptor alpha-2/beta-2/gamma-2 5 Target ID: CHEMBL2111413 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25798598	Agonist 2470	40.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Seizure disorders 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017533s055lbl.pdf	Primary		Approved 8043	KLONOPIN Approved Use INDICATIONS & USAGE Seizure Disorders: Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and . In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Panic Disorder: Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder. Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Launch Date 1.71071996E11
Panic disorder 19 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017533s055lbl.pdf	Primary		Approved 8043	KLONOPIN Approved Use INDICATIONS & USAGE Seizure Disorders: Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and . In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Panic Disorder: Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder. Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Launch Date 1.71071996E11

C_max

Value	Dose	Co-administered	Analyte	Population
2.3 ng/mL EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3 ng/mL REVIEW https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		CLONAZEPAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
102 ng × h/mL EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
339 ng × h/mL REVIEW https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		CLONAZEPAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40 h REVIEW https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		CLONAZEPAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
15% EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 mg single, intramuscular Dose: 2 mg Route: intramuscular Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	Sources: https://pubmed.ncbi.nlm.nih.gov/12646763
2 mg single, intravenous Dose: 2 mg Route: intravenous Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	Sources: https://pubmed.ncbi.nlm.nih.gov/12646763
2 mg single, oral Dose: 2 mg Route: oral Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	Sources: https://pubmed.ncbi.nlm.nih.gov/12646763
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	Disc. AE: Somnolence, Depression... AEs leading to discontinuation/dose reduction: Somnolence (7%) Depression (4%) Nervousness (1%) Dizziness (1%) Ataxia (1%) Intellectual disability (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
6 mg 1 times / day steady, oral Studied dose Dose: 6 mg, 1 times / day Route: oral Route: steady Dose: 6 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3279721	unhealthy Health Status: unhealthy Condition: depression Sources: https://pubmed.ncbi.nlm.nih.gov/3279721	Sources: https://pubmed.ncbi.nlm.nih.gov/3279721

AEs

AE	Significance	Dose	Population
Ataxia	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Dizziness	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Intellectual disability	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Nervousness	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Depression	4% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Somnolence	7% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 717 CYP2E1 790 UGT 31	CYP3A 172 BCRP 515	CYP 70 UGT 27

Drug as perpetrator

Target	Modality	Activity
CYP 132	inducer 1440 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001218/	no
UGT 54	inducer 1440 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001218/	no
UGT 54	inhibitor 3045 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001218/	no
CYP2B6 884	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	weak
CYP2E1 871	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/9574817/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
BCRP 515	substrate 3113 Sources: https://www.wjgnet.com/2220-3192/full/v3/i4/153.htm	no
CYP3A 172	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/017533s061lbl.pdf#page=2 Page: 2.0	yes
CYP3A4 1601	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203763/	yes	yes (pharmacogenomic study) Comment: The statistical analysis displayed significant association between the patients’ CYP3A4 expression and the stable plasma concentrations of clonazepam normalized by the dose and the patient’s bodyweight. Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203763/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3756	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3756
ZINC	ZINC000003813003	http://zinc15.docking.org/substances/ZINC000003813003
eMolecules	535779	https://www.emolecules.com/cgi-bin/more?vid=535779

PubMed

Title	Date	PubMed
Letter: Clonazepam in the treatment of drug-induced dyskinesia.	1975 Feb 1	1111773
Pharmacological options for the treatment of Tourette's disorder.	2001	11772131
LSD-induced Hallucinogen Persisting Perception Disorder treated with clonazepam: two case reports.	2001	11475916
Sleep disorders in patients with Parkinson's disease: epidemiology and management.	2001	11463132
[Clonazepam in the treatment of labile arterial hypertension in the elderly].	2001	11417185
Treatment of typical absence seizures and related epileptic syndromes.	2001	11393330
Tourette syndrome: clinical characteristics and current management strategies.	2001	11393328
Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis.	2001	11299059
[Clonazepam in therapy of neurogenic syncopal states].	2001	11243029
Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone.	2001 Apr	11393275
Random total antiepileptic drug levels and seizure control during pregnancy.	2001 Apr	11331496
Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam.	2001 Apr	11313161
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells.	2001 Apr	11266385
Carbamazepine treatment of corticosteroid-induced mood disorder.	2001 Aug	11511412
Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.	2001 Aug	11498064
Mitochondria recycle Ca(2+) to the endoplasmic reticulum and prevent the depletion of neighboring endoplasmic reticulum regions.	2001 Aug 3	11358971
[Primary orthostatic tremor: slow harmonic component as responsible of inestability].	2001 Aug-Sep	11485726
Pharmacoepidemiologic investigation of a clonazepam-carbamazepine interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients.	2001 Dec	11763006
Direct LC analysis of five benzodiazepines in human urine and plasma using an ADS restricted access extraction column.	2001 Dec	11600302
Roles for mitochondrial and reverse mode Na+/Ca2+ exchange and the plasmalemma Ca2+ ATPase in post-tetanic potentiation at crayfish neuromuscular junctions.	2001 Dec 15	11739570
Sleep disorders.	2001 Feb	11471763
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction.	2001 Feb	11258050
Focal stiff-person syndrome.	2001 Feb	11257937
[Antiepileptic drugs and neuropathic pain].	2001 Feb 16-28	11333392
[Cortico-subcortical electrophysiological study during the effects of benzodiazepines in patients with panic disorders].	2001 Feb 16-28	11333385
Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats.	2001 Jan	11151029
Perioral myoclonia with absence seizures: a rare epileptic syndrome.	2001 Jan-Mar	11313219
Case report: unexplained syncope explained.	2001 Jul	11494931
Infantile status epilepticus in Tunisia. Clinical, etiological and prognostic aspects.	2001 Jul	11488648
Acquired epileptiform opercular syndrome: a case report and results of single photon emission computed tomography and computer-assisted electroencephalographic analysis.	2001 Jul	11377005
Spectrofluorimetric determination of vigabatrin and gabapentin in dosage forms and spiked plasma samples through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.	2001 Jul-Aug	11501899
Burning mouth syndrome after taking clonazepam.	2001 Jul-Aug	11485137
Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam.	2001 Jun	11437823
Melatonin therapy for REM sleep behavior disorder.	2001 Jun	11422870
[3H]Flunitrazepam binding to recombinant alpha1beta2gamma2S GABAA receptors stably expressed in HEK 293 cells.	2001 May	11393809
Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm.	2001 May 18	11368960
Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series.	2001 May-Jun	11340418
Stiff leg syndrome: case report.	2001 Nov	11748762
West syndrome: the Philippine experience.	2001 Nov	11701266
Kinetic and pharmacological properties of GABA(A) receptors in single thalamic neurons and GABA(A) subunit expression.	2001 Nov	11698521
Increased [Mg2+]o reduces Ca2+ influx and disruption of mitochondrial membrane potential during reoxygenation.	2001 Nov	11668073
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.	2001 Oct	11704788
2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands.	2001 Oct	11557354
Effect of clonazepam treatment on antipsychotic drug-induced Meige syndrome and changes in plasma levels of GABA, HVA, and MHPG during treatment.	2001 Oct	11555353
A successful clonazepam treatment without tolerance in a patient with spontaneous oral dyskinesia.	2001 Oct	11513361
[Efficacy of anticonvulsants on acute encephalitis with refractory, repetitive partial seizures (AERRPS)].	2001 Sep	11558140
Topiramate as a mood stabilizer.	2001 Sep	11552774
Hyperekplexia in neonates.	2001 Sep	11524514
Evaluation of polymeric nanoparticles composed of cholic acid and methoxy poly(ethylene glycol).	2001 Sep 11	11532566
Myoclonus during prolonged treatment with sertraline in an adolescent patient.	2001 Summer	11436961

Patents

Sample Use Guides

In Vivo Use Guide

Seizure Disorders: Adults: The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg. Clonazepam is available as a tablet or an orally disintegrating tablet (wafer). The tablets should be administered with water by swallowing the tablet whole. The orally disintegrating tablet should be administered as follows: After opening the pouch, peel back the foil on the blister. Do not push tablet through foil. Immediately upon opening the blister, using dry hands, remove the tablet and place it in the mouth. Tablet disintegration occurs rapidly in saliva so it can be easily swallowed with or without water.

Route of Administration: Oral

In Vitro Use Guide

Clonazepam (100 nM) increased inhibitory postsynaptic current (IPSC) decay time constants in rat thalamic nuclei-the reticular nucleus (nRt) (from 44.3 to 77.9 ms, P < 0.01) but not in the ventrobasal (VB) complex..

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:53:24 UTC 2021` Edited by `admin` on `Fri Jun 25 20:53:24 UTC 2021`
Record UNII	5PE9FDE8GB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLONAZEPAM

Official Name

English

NSC-179913

Code

English

CLONAZEPAM [JAN]

Common Name

English

RIVOTRIL

Brand Name

English

RO-5-4023

Code

English

CLONAZEPAM [MART.]

Common Name

English

RIVATRIL

Brand Name

English

RO 5-4023

Code

English

2H-1,4-BENZODIAZEPIN-2-ONE, 5-(2-CHLOROPHENYL)-1,3-DIHYDRO-7-NITRO-

Systematic Name

English

CLONAZEPAM [ORANGE BOOK]

Common Name

English

5-(O-CHLOROPHENYL)-1,3-DIHYDRO-7-NITRO-2H-1,4-BENZODIAZEPIN-2-ONE

Common Name

English

CLONAZEPAM [MI]

Common Name

English

KLONOPIN

Brand Name

English

CLONAZEPAM [EP MONOGRAPH]

Common Name

English

RO-54023

Code

English

CLONAZEPAM [WHO-DD]

Common Name

English

CLONAZEPAM [INN]

Common Name

English

RAVOTRIL

Brand Name

English

CLONAZEPAM [VANDF]

Common Name

English

CLONAZEPAM CIV [USP-RS]

Common Name

English

CLONAZEPAM [HSDB]

Common Name

English

CLONAZEPAM CIV

Common Name

English

CLONAZEPAM [USAN]

Common Name

English

CLONAZEPAM [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175694